Comparative Pharmacology
Head-to-head clinical analysis: ORTHO NOVUM 1 35 21 versus ZELVYSIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO NOVUM 1 35 21 versus ZELVYSIA.
ORTHO-NOVUM 1/35-21 vs ZELVYSIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin (FSH and LH) secretion via negative feedback, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial lining, impairing sperm penetration and implantation.
ZELVYSIA (molnupiravir) is a prodrug that is metabolized to the ribonucleoside analog NHC-triphosphate, which inhibits SARS-CoV-2 replication by inducing viral RNA mutagenesis via incorporation into viral RNA by the viral RNA-dependent RNA polymerase, leading to error catastrophe.
One tablet orally once daily for 21 days, followed by 7 placebo tablets. Each tablet contains 1 mg norethindrone and 0.035 mg ethinyl estradiol.
For uncomplicated Gram-negative infection: 30 mg/kg intravenous loading dose over 1 hour, followed by 10 mg/kg intravenous maintenance dose over 1 hour every 24 hours. For complicated infections: 30 mg/kg loading, then 20 mg/kg every 24 hours. Infuse over 2 hours for maintenance doses.
None Documented
None Documented
Norethindrone: 7-9 hours (terminal); Ethinyl estradiol: 13-27 hours (terminal). At steady state, clinical contraceptive efficacy is maintained with daily dosing.
Terminal elimination half-life is 3.5 hours (range 2.5–5 hours); clinically relevant for dosing interval adjustments in renal impairment.
Renal (approx. 40% as metabolites, <10% unchanged), fecal (approx. 60% as metabolites, primarily via bile).
Primarily renal excretion (70% as unchanged drug); additional 20% fecal/biliary; 10% metabolized.
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive